Avantor (NYSE:AVTR) Receives “Neutral” Rating from UBS Group

UBS Group restated their neutral rating on shares of Avantor (NYSE:AVTR) in a research report report published on Friday morning, MarketBeat Ratings reports. The firm currently has a $25.00 target price on the stock, down from their previous target price of $29.00.

A number of other analysts have also commented on the company. Barclays reduced their target price on Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a report on Friday, October 25th. Wells Fargo & Company reduced their price objective on Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a report on Monday, October 28th. Royal Bank of Canada restated an “outperform” rating and set a $34.00 target price on shares of Avantor in a research note on Thursday, September 26th. Finally, Robert W. Baird reduced their price target on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research note on Monday, October 28th. Three equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, Avantor currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.38.

Avantor Price Performance

Shares of AVTR opened at $22.14 on Friday. Avantor has a twelve month low of $19.59 and a twelve month high of $28.00. The company has a market capitalization of $15.07 billion, a P/E ratio of 48.13, a price-to-earnings-growth ratio of 3.42 and a beta of 1.28. The firm has a 50 day moving average of $21.46 and a 200 day moving average of $23.34. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84.

Institutional Trading of Avantor

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. MassMutual Private Wealth & Trust FSB grew its position in shares of Avantor by 99.5% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company’s stock valued at $26,000 after acquiring an additional 625 shares during the period. UMB Bank n.a. purchased a new stake in Avantor in the third quarter worth about $49,000. Nisa Investment Advisors LLC raised its stake in shares of Avantor by 69.6% in the third quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock worth $53,000 after buying an additional 835 shares during the period. GAMMA Investing LLC lifted its position in shares of Avantor by 89.9% during the 3rd quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock valued at $70,000 after buying an additional 1,285 shares in the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt grew its stake in shares of Avantor by 278.0% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 5,031 shares of the company’s stock valued at $130,000 after acquiring an additional 3,700 shares during the period. 95.08% of the stock is owned by hedge funds and other institutional investors.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.